Formulation Process
A detailed record of the methodology, testing protocol, and manufacturing standards applied in developing the SkinTech formula.
Three years. 40+ iterations. One formula.
The SkinTech formulation process was designed to pharmaceutical compounding standards — not cosmetic industry norms. The difference is significant: cosmetic formulation typically optimizes for consumer perception (texture, scent, skin feel) with active ingredient inclusion as a secondary consideration. Pharmaceutical compounding inverts this: mechanism and concentration are primary, with sensory properties addressed secondarily.
The result of applying that inverted priority set to a consumer product was three years of development, 40+ rejected formulations, and a final product that does fewer things than most products claim, and actually does them.
Mechanism-first ingredient selection
The formulation process began not with ingredient sourcing but with a clinical question: what are the primary mechanisms of skin aging, barrier degradation, and inflammatory damage, and what are the most effective known compounds for each?
The answer identified five primary target mechanisms: (1) free radical oxidative damage, (2) chronic inflammatory signaling, (3) UV-induced collagen matrix degradation, (4) epidermal moisture retention failure, and (5) barrier lipid depletion. Each mechanism was matched to the best available active compound — not the most marketable one.
Concentration and ratio development
Identifying the right ingredients is the simpler half of formulation. The harder half is determining the concentration at which each ingredient produces its documented mechanism without destabilizing the formula, interacting adversely with other actives, or producing unacceptable sensory properties for daily use.
The spin trap (PBN) concentration was the most technically demanding variable. At insufficient concentration, the spin-adduct mechanism is negligible. At excess concentration, the compound affects formula pH stability and alters the interaction dynamics with the plant stem cell complex. Across 40+ iterations, the primary variable being tested was the concentration matrix — the specific ratio of PBN to stem cell extract to ceramide loading at which all mechanisms operate simultaneously without mutual interference.
Manufacturing partner selection: CoValence Laboratories
Once the formula concept was established, scale-up manufacturing required an ISO-certified facility capable of handling pharmaceutical-grade actives including PBN, which requires controlled handling protocols not available in standard cosmetic manufacturing environments.
CoValence Laboratories (Island Kinetics, Inc.), Chandler, Arizona, was selected as the manufacturing partner. CoValence holds ISO 22716 certification — the international standard for cosmetic Good Manufacturing Practice — and is registered with the FDA as an establishment authorized to produce OTC-registered products. The facility operates under FDA-inspected cGMP protocols with documented quality management systems.
Raw material qualification
All raw materials used in the SkinTech formula undergo CoValence's standard incoming material qualification protocol before entering production. This includes documentation review (Certificates of Analysis, Safety Data Sheets), physical and chemical identity testing, and microbiological screening where applicable.
Client-supplied active ingredients — in SkinTech's case, the pharmaceutical-grade spin trap compound — are held to the same incoming quality standards as CoValence-stocked materials. They are not used until they meet the facility's raw material specification requirements.
Formula replication and R&D sample development
CoValence's standard development process begins with formula replication — rebuilding the client's developed formula using CoValence's stocked materials while incorporating the client's specified active compounds. This step produces the first CoValence-manufactured sample for evaluation.
The R&D fee structure covered the initial sample and two revisions. Formulas not meeting specification were restarted with no additional R&D cost — a provision that reflects the expectation that pharmaceutical-level formulation work requires iteration at the manufacturing scale as well as the bench scale.
Accelerated stability testing
Accelerated stability testing estimates a product's shelf life and identifies potential physical or chemical instability under compressed timeframes. CoValence's protocol places samples under multiple controlled temperature conditions simultaneously and monitors physical characteristics at defined intervals.
The Night Cream formula (ERX0-5001, formula T090517C) completed stability testing in both 4 oz glass jars and 30mL plastic pump bottles. Testing ran from October 18, 2017 through January 9, 2018, across four temperature conditions: 4°C (refrigerated), 25°C (ambient), 40°C (accelerated aging), and 45°C (stress condition).
Challenge testing (microbial)
Challenge testing — required by CoValence for all water-containing formulations — evaluates the effectiveness of the preservation system under microbial challenge conditions. A panel of standardized organisms (bacteria and fungi) is introduced into the formula at defined concentrations, and the formula's ability to reduce those populations to acceptable levels within specified timeframes is measured.
Challenge testing timeline: 5–6 weeks. The Leuconostoc ferment filtrate preservation system met challenge testing requirements across the formula's water activity range.
RIPT — Repeat Insult Patch Test
The Repeat Insult Patch Test (RIPT) is a human clinical safety evaluation that assesses both primary irritation potential and sensitization potential under repeated exposure conditions. The protocol involves an induction phase (repeated patch applications over multiple weeks) followed by a challenge phase, with graded evaluation of any dermal response.
RIPT is recommended for all cosmetic products. For SkinTech, it was conducted on all formula variants prior to commercial launch. Products that do not undergo RIPT are legally required to carry a label statement disclosing that the product has not been tested for safety.
Packaging qualification and fill testing
Formula-package compatibility is a distinct evaluation from formula stability. The same formula can perform differently in glass versus plastic, in pump versus jar configurations, at different fill weights. CoValence's packaging qualification protocol includes a 10% incoming inspection of packaging components and a thorough quality and quantity check during the filling process.
The SkinTech formula was stability-tested in both primary packaging formats: 4 oz glass jars and 30mL plastic pump bottles. Compatibility was confirmed for both.
FDA establishment listing and OTC registration
EffectsRx, LLC products are listed with the FDA through CoValence's established drug registration and listing system. CoValence holds FDA establishment registration and submits all product listings required by the FDA on behalf of client formulas. This registration authorizes OTC product production and is subject to periodic FDA facility inspection.
The established listing creates a regulatory paper trail from the finished product on shelf to the manufacturing batch record, raw material CoAs, stability data, and RIPT documentation — a complete chain of custody that supports any future regulatory review or quality inquiry.
Complete active ingredient reference.
All active ingredients in the SkinTech formula, with INCI names, function classification, and mechanism summary.
| INCI Name | Common name | Primary function |
|---|---|---|
| Phenyl N-tert-butylnitrone | Spin Trap (PBN) | ROS scavenging; NF-κB inhibition; anti-inflammatory signaling |
| Symphytum Officinale Root Cell Extract | Comfrey root stem cell | Cell turnover activation; smooth tone without physical exfoliation |
| Buddleja Davidii Meristem Cell Culture | Butterfly bush stem cell | UVA protection; MMP inhibition; collagen preservation |
| Sodium Hyaluronate (L) | Low mol. weight hyaluronic acid | Dermal moisture delivery; humectancy; natural exfoliation support |
| Ceramide NP | Ceramide (milk-derived) | Barrier lipid restoration; TEWL reduction; liposome-delivered |
| Glucosamine HCl (D) | Glucosamine hydrochloride | Glycosaminoglycan precursor; connective tissue and elasticity support |
| Laminaria Digitata Extract | Sea kelp | Vitamin/mineral nourishment; tissue invigoration; fine line appearance |
| Ascorbyl Palmitate | Vitamin C ester (fat-soluble) | Antioxidant; oxidative damage protection; hyperpigmentation correction |
| Retinyl Palmitate | Vitamin A ester | Skin renewal support; anti-aging; appearance of aged/blemished skin |
| Leuconostoc / Radish Root Ferment Filtrate | Fermented radish root | Natural preservation; antimicrobial; paraben- and phenoxyethanol-free |